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p66shc is increased in response to cell stress, and these in-
creases regulate growth factor actions. These studies were con-
ducted todeterminehowp66shc alters IGF-I-stimulatedSrc acti-
vation, leading to decreased IGF-I actions.Our results show that
p66shc binds to Src through a polyproline sequence motif con-
tained in the CH2 domain, a unique domain in p66shc, and IGF-I
stimulates this interaction.Disruptionof this interactionusing a
synthetic peptide containing the p66shc polyproline domain or
expression of a p66shc mutant containing substitutions for the
proline residues (P47A/P48A/P50A) resulted in enhanced Src
kinase activity, p52shc phosphorylation, MAPK activation, and
cell proliferation in response to IGF-I. To determine the mech-
anism of inhibition, the full-length CH2 domain and intact
p66shc were tested for their ability to directly inhibit Src kinase
activation in vitro. The CH2 domain peptide was clearly inhibi-
tory, but full-length p66shc had a greater effect. Deletion of the
C-terminal Src homology 2 domain in p66shc reduced its ability
to inhibit Src kinase activation. These findings demonstrate that
p66shc utilizes a novel mechanism for modulating Src kinase
activation and that this interaction is mediated through both its
collagen homologous region 2 and Src homology 2 domains.
Shc (Src homology collagen) is an important adaptor pro-
tein that couples tyrosine kinase receptor signaling to Ras/
MAPK2 activation. As a result of alternative translation initia-
tion sites and mRNA splicing, a single gene produces three
isoforms of Shc, p66/p52/p46shc (1, 2). Three important
tyrosines, Tyr239, Tyr240, and Tyr317, in p52shc are phosphory-
lated following growth factor stimulation. These phosphoty-
rosines provide binding sites for recruiting Grb2 (growth factor
receptor-bound 2), which initiates the sequence of events lead-
ing to MAPK activation (3, 4). Therefore, p52shc is believed to
play a positive growth-stimulatory role in a variety of cell types
(4, 5).More recently, p52shc-mediated signaling has been shown
to be essential for tumor progression in mouse models of
human breast cancer (6). In smooth muscle cells (SMC),
exposed to hyperglycemia, p52shc-mediated signaling has been
demonstrated to be important for insulin-like growth factor-I
(IGF-I) signaling and biological actions. Following IGF-I recep-
tor stimulation, the integral membrane protein SHPS-1 (Src
homology 2 domain-containing protein-tyrosine phosphatase
substrate-1) is tyrosine-phosphorylated, and a signaling com-
plex composed of SHP-2 (Src homology 2 domain-containing
protein-tyrosine phosphatase-2), c-Src, and p52shc is assembled
on SHPS-1. This induction of p52shc phosphorylation and sub-
sequent activation of MAPK enhance the sensitivity of smooth
muscle cells to themitogenic actions of IGF-I (7). This has been
demonstrated in cultured cells as well as experimental animals
(8). In contrast to p52shc, the p66 isoformof Shc has been shown
to inhibit both epidermal growth factor- and IGF-I-stimulated
MAPK activation and cell proliferation (2, 9, 10). In addition,
p66shc has been shown to regulate the oxidative stress response
through its unique CH2 domain (11). p66shc expression is
increased during states of oxidative stress (12–14) and hyper-
glycemia-induced oxidative stress (15, 16). This increase in
p66shc is believed to be proapoptotic in some cell types, and
genetic ablation of p66shc in mice is associated with reduced
generation of ROS in response to hyperglycemia and reduced
apoptosis (15, 17, 18).
In SMC, hyperglycemic stress and the increase in reactive
oxygen species generation can lead to apoptosis, but if growth
factors, including IGF-I, are present, theMAPK and cell prolif-
eration responses are increased (19–22). In this cell type, the
phosphorylation of p52shc in response to IGF-I is enhanced by
hyperglycemia when compared cells are maintained in 5 mM
glucose (23). Importantly, this response of p52shc to IGF-I in
response to hyperglycemic stress is modulated by c-Src, which
directly phosphorylates p52shc (24). Because both p52 and
p66shc isoforms are induced in response to hyperglycemic stress
yet they have been reported to mediate different actions, we
investigated the role of p66shc in modulating p52shc activation
and showed that its overexpression attenuated p52shc phos-
phorylation and inhibited themitogenic response to IGF-I (10).
Therefore, these studies were undertaken to determine the
mechanismbywhich p66shcmodulates IGF-I-stimulated p52shc
activation and mitogenesis.
EXPERIMENTAL PROCEDURES
Human IGF-I was a gift from Genentech (South San Fran-
cisco, CA). Dulbecco’s modified Eagle’s medium containing
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4500 mg of glucose/liter (DMEM-H), penicillin, streptomycin,
and anti-phospho-Y419Src antibody were purchased from
Invitrogen. The Grb2 polyclonal antibody and the monoclonal
phosphotyrosine antibody (PY99) were purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA). Polyvinyl difluoride
membrane (Immobilon P), SHPS-1 antibody, and activated Src
were purchased from Millipore Corp. (Billerica, MA). The Src
antibodywas purchased fromEMDChemicals, Inc. (SanDiego,
CA). The Shc antibody and the Grb2 monoclonal antibody
were purchased from BD Biosciences. The total Erk1/2, phos-
pho-Erk1/2, and HA antibodies were obtained from Cell Sig-
naling (Danvers, MA). Autoradiographic film was purchased
from Danville Scientific, Inc. (South Plainfield, NJ). All other
reagents were purchased from Sigma unless otherwise stated.
Four synthetic peptides were prepared that contained the TAT
sequence that confers cell permeability followed by either the
proline-rich region of the CH2 domain of p66shc sequence,
termed p189 (YARAAARQARALGPILPPLPGD; the underline
indicates residues 42–52 in p66shc) or a control peptide that
contained an equal number of prolines (YARAARQARAGP-
PATPAQPGLH). An additional peptide contained the se-
quence homologous to Src that contains Tyr328, termed p136
(YARAAARQARAVQLYAVVSEE; the underline indicates res-
idues 325–334 in Src). A tyrosine-phosphorylated form of p136
peptide, termed p226, was used in in vitro binding and Src
kinase assays as well as in living cells. The peptides were syn-
thesized by the Protein Chemistry Core Facility (University of
North Carolina, Chapel Hill, NC). These sequences were veri-
fied by mass spectrometry.
Cell Culture—Porcine smoothmuscle cells (pSMC)were iso-
lated from porcine aortas using a method that had been previ-
ously described (25). The cells were maintained in DMEM-H
(25 mM glucose) supplemented with 10% fetal bovine serum
(Hyclone, Logan,UT), streptomycin (100g/ml), andpenicillin
(100 units/ml). The cells that were used in these experiments
were used between passages 5 and 15. Porcine aortic endothe-
lial cells were isolated from young pigs. The aorta was rinsed
through with 37 °C phosphate-buffered solution three times
and incubated with medium (M199, Cellgro) containing colla-
genase (1 mg/ml) for about 5 min. The medium was collected
and centrifuged at 3000 rpm for 5 min. The pellet was sus-
pended with the same medium and plated into a 150-cm2 flask
(Corning Glass). After attachment (overnight), the medium
was refreshed. The purity of the isolated cells was verified by
Von Willebrand factor (Dako) staining and morphological
observation. Cells processed in this manner formed a homoge-
nous monolayer. For experiments, the cells were plated in
either 10-cmor 6-cmdishes (CorningGlass) and fedwithM199
containing 20% fetal bovine serum, 25 mM glucose, streptomy-
cin (100 g/ml), penicillin (100 unit/ml), and sodium pyruvate
(100 nM). The cells that were used in these experiments were
used between passages 5 and 10.
Construction of cDNAs and Establishment of p66shc Si, EVC,
p66shcWT-HA, p66shc 3F-HA, p66shc P3A-HA, p66shc SH2, Src
WT-HA, Src 2F-HA, and LacZ Cells—pSMC expressing small
hairpin RNA sequence targeting p66shc (p66shc Si) and corre-
sponding control pSMCexpressing empty vector (EVC), pSMC
expressing wild type (WT) p66shc (p66shc WT-HA), and corre-
sponding control pSMC expressing LacZ (LacZ) have been
described previously (10). In addition, pSMC expressing WT
Src (SrcWT-HA) and Src Y329F/Y360F (Src 2F-HA) also have
been previously described (24). The p66shc WT-HA vector was
used as a template to generate the p66shc Y349F/Y350F/Y427F
(p66shc 3F) by two rounds of PCR. The first round of PCR gen-
erated p66shc Y349F/Y350F using forward and reverse primers:
5-CCACCTGACCATCAGTTCTTTAATGACTTCCCG-
GGG-3 and 5-CCCCGGGAAGTCATTAAAGAACTGAT-
GGTCAGGTGG-3. The first round PCR product was used as
a template for second round PCR to generate p66shc Y349F/
Y350F/Y427F using forward and reverse primers: 5-TTGA-
TGATCCCTCCTTTGTCAACGTCCAGAACC-3 and 5-
GGTTCTGGACGTTGACAAAGGAGGGATCATCAA-3.
The underlined bases indicate the substitutions that change
tyrosine to phenylalanine. The forward and reverse primers




bases indicated the substitutions that change proline to alanine.
Point mutations were introduced using standard method
(QuikChange, Stratagene (La Jolla, CA)). The p66shc WT-HA
vector was used as a template to generate the p66shc SH2
domain deletion mutant (deleting amino acids 487–579, p66shc
SH2) by PCR. The forward and reverse primers thatwere used
to generate the PCR product were 5-cac cat gga tct cct gcc ccc
caa g-3 and 5-tta AGCGTAATCTGGAACATCGTAT-
GGGTA ctc ccc tcg gag ctg ctc agc c-3. The PCR product
contained a Kozak sequence (CACC) at the 5-end and a HA
(capitalized) sequence at the 3-end. All constructions were
verified byDNA sequencing. 293FT cells (Invitrogen)were pre-
pared for generation of virus stocks, and pSMC expressing
p66shc 3F-HA and p66shc P3A-HA were established using pro-
cedures that were described previously (10).
Immunoprecipitation and Immunoblotting—The cell mono-
layers were lysed in a modified radioimmunoprecipitation
assay buffer (1% Nonidet P-40, 0.25% sodium deoxycholate, 1
mM EGTA, 150 mM NaCl, and 50 mM Tris-HCl, pH 7.5) in the
presence of protease inhibitors (10 g/ml aprotinin, 1 g/ml
leupeptin, 1 mM phenylmethylsulfonyl fluoride, and 1 g/ml
pepstatin) and phosphatase inhibitors (25 mM sodium fluoride
and 2 mM sodium orthovanadate). Coimmunoprecipitation
was typically performed by incubating 0.5 mg of cell lysate with
1 g of each of the following antibodies: anti-Shc, Grb2, Src,
SHPS-1, or PY99 at 4 °C overnight. The immunoprecipitates
were immobilized using protein A orG beads for 2 h at 4 °C and
washed three times with the same lysis buffer containing pro-
tease and phosphatase inhibitors. The precipitated proteins
were eluted in 40 l of 2 Laemmli sample buffer, boiled for 5
min, and analyzed by SDS-PAGE followed by immunoblotting.
Immunoblotting was performed as described previously (10)
using a dilution of 1:1000 for anti-Shc, phospho-Erk1/2, Erk1/2,
p419Src, and Src and 1:5000 for anti-Grb2. The membranes
were striped for repeat immunoblotting only for loading con-
trols. The proteins were visualized using enhanced chemilumi-
nescence (Pierce).
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In Vitro Binding Assay—The in vitro [35S]methionine (MP
Biomedical, Solon, OH)-labeled intact p66shc and p52shc, p66shc
P3Amutant,WTCH2 domain, and P3A-mutatedCH2 domain
of p66shc were generated by a transcription/translation (TNT)
reaction (Promega, Madison, WI). An aliquot of the individual
TNT mixture (0.4 M total protein for each) or different com-
binations of them, as indicated, were incubated with 200 ng of
purified active Src (Millipore Corp.) in binding buffer (HEPES,
pH 7.6, 50 mM KCl, 1 mM dithiothreitol, 0.5 mM phenylmethyl-
sulfonyl fluoride, 0.2% Triton X-100, and 10% glycerol) in the
presence or absence of p189 or p226 (1 g/ml), using a 100-l
final volume and rotation for 2 h at 4 °C. 0.6 g of anti-Src
antibody and 30 l (50% slurry) of protein A/G-agarose beads
were then added and incubated for another 2 h. After extensive
washing with the binding buffer, the precipitated proteins were
eluted in 30 l of 2 Laemmli sample buffer, boiled for 5 min,
and separated using 10% SDS-PAGE. The images were devel-
oped and analyzed using a Storm860 PhosphorImager (Amer-
sham Biosciences).
In Vitro Src Kinase Assay—Src kinase activity was deter-
mined in vitrousing a Src kinase assay kit (MilliporeCorp.). The
kinase assay was performed following the manufacturer’s
instructions. Briefly, the p66shc (WT or P3A mutant), p52shc,
and CH2 domain (WT or P3A mutant) were generated by a
TNT reaction (Promega). An aliquot of the TNT mixture of
each (final concentration 0.4 M protein) or combinations of
them as indicated were incubated with 2.5 units of purified
active Src, 150 M Src kinase substrate peptide (KVEKIGEG-
TYGVVYK), and 10 Ci of [-32P]ATP in Src reaction buffer
(25 mM Tris-HCl, pH 7.2, 25 mM MgCl2, 1.25 mM MnCl2, 0.5
mM EGTA, 60 M sodium orthovanadate, 0.5 mM dithiothrei-
tol, and 100 m ATP) in the presence or absence of p189 or
p226. Themixtures were incubated for 30min at room temper-
ature. The amount of 32P that was incorporated into the sub-
strate peptide, which reflects the activity of Src kinase, was
quantified by a liquid scintillation counter (Packard, Meriden,
CT).
Cell Proliferation Assay—Assessment of pSMC proliferation
was performed as described previously (26). Briefly, cells were
incubated with or without IGF-I (50 ng/ml) in serum-free
DMEM-H containing 0.2% platelet-poor plasma for 48 h, and
cell number in each well was counted. For assessment of
porcine aortic endothelial cell proliferation, cells were
plated at 2  104 in each well of a 24-well plate in M199
containing 20% fetal bovine serumand 25mMglucose. The next
day, the mediumwas replaced withM199 containing 0.2% fetal
bovine serum and 25mM glucose. After 14–16 h, the cells were
fedwith the samemedium in the presence or absence of p189 or
a control peptide for 2 h of incubation before being exposed or
not to IGF-I (50 ng/ml). After incubation for 48 h, the cell num-
ber was determined. Each treatment was analyzed in triplicate,
and the results represent mean values of three independent
experiments.
CellMigration Assay—Wounding of control and p66shcWT-
and p66shc P3A-overexpressing pSMC was performed as de-
scribed previously (27). The wounded monolayers were
exposed to IGF-I (100 ng/ml) for 48 h at 37 °C. The cells were
fixed and stained (Diff Quick, Dade Behring, Inc., Newark, DE),
and the number of cells migrating into the wound area was
counted. At least eight of the previously selected 1-mm areas at
the edge of the wound were counted for each data point.
Statistical Analysis—Chemiluminescent images obtained
were scanned using a DuoScan T1200 (AGFA, Brussels, Bel-
gium). The band intensities of the scanned images were
within the linear range of detection and were analyzed using
NIH Image J, version 1.37V. The results that are shown in all
experiments are representative of at least three separate
experiments unless otherwise stated and expressed as the
mean  S.E. Student’s t test was used to compare differences
between control and treatment groups or control cells and cells
expressing mutant proteins. p  0.05 was considered statisti-
cally significant.
RESULTS
p66shc Inhibits IGF-I Signaling via Disrupting SHPS-1
p52shcGrb2 Complex Formation—To examine the possibility
that p66shcwas competitively inhibitingGrb2 binding to p52shc,
we substituted the tyrosines in p66shc that have homology to the
p52shc-Grb2 binding sites with phenylalanine and expressed
this 3F mutant form of p66shc in pSMC. The expression level
was comparable with cultures in which WT p66shc had been
overexpressed (Fig. 1A). p66shc 3F did not associate with Grb2
after IGF-I stimulation (Fig. 1B). However, overexpression of
p66shc 3F, like p66shc WT, impaired IGF-I-stimulated p52shc-
Grb2 recruitment (e.g. a 1.20  0.05-fold increase in p66shc 3F
cells versus a 2.23  0.17-fold increase in LacZ cells after
10-min IGF-I stimulation; p  0.05) (Fig. 1B). Similarly, when
formation of the SHPS-1 signaling complex was examined fol-
lowing IGF-I stimulation, overexpression of p66shc 3F inhibited
IGF-I-dependent p52shc association with SHPS-1 (e.g. a 1.46 
0.05-fold increase in p66shc 3F versus a 2.10 0.04-fold increase
in LacZ cells after 10-min IGF-I stimulation;p 0.01) andGrb2
recruitment to the SHPS-1 complex (e.g. a 1.35  0.07-fold
increase in p66shc 3F versus a 2.49  0.11-fold increase in LacZ
after 10-min IGF-I stimulation; p  0.01) although it had no
effect on IGF-I-stimulated SHPS-1 phosphorylation (Fig. 1C).
In addition, we detected increased p66shc association with
SHPS-1 after IGF-I stimulation in both the p66shc 3F- and WT
p66shc-overexpressing cells, compared with LacZ cells, demon-
strating that the ability of p66shc to bind to the SHPS-1 complex
was not impaired by the 3F mutation (Fig. 1C). Because our
previous studies have shown that Src kinase phosphorylates
p52shc (24) and that p52shc phosphorylation is inhibited consti-
tutively by p66shc overexpression (10), these results suggested
that p66shc could be inhibiting Src kinase.
p66shc Binds Directly to Src through Both Polyproline-SH3
and -SH2 Phosphotyrosine Site Interactions—Overexpression
of p66shc impaired p52shc recruitment to Src and enhanced
p66shc association with Src after IGF-I stimulation (Fig. 2A).
Similarly, the p66shc 3F mutant bound to Src, and it also
impaired p52shc-Src association after IGF-I stimulation (Fig.
2A). The amino acid sequences of p66shc and p52shc are identi-
cal except for the addition of a unique CH2 domain in the N
terminus of p66shc. A PPLP motif is present within the CH2
domain; thus, in addition to the phosphotyrosine-SH2 (Tyr(P)-
SH2) domain interaction that occurs between p52shc and Src,
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p66shc could potentially associate with Src through a PXXP-
SH3 domain interaction (Fig. 2B). To determine if this domain
interacted directly with Src, an in vitro binding assay was per-
formedusing a cell-free expression system. Expression of p66shc
and p52shcwas detected (Fig. 2C, lanes 1 and 7). Co-incubation
of activated Src with p66shc resulted in their direct association
(Fig. 2C, lane 2). This binding was disrupted by co-incubating
with a synthetic peptide, termedp189,which contains the PPLP
motif of p66shc (Fig. 2C, lane 3). As predicted, p52shc bound
directly to Src (Fig. 2C, lane 4). When both p66shc and p52shc
were incubated with activated Src, Src binding to p52shc was
impaired (Fig. 2C, lane 5 versus lane 4). This inhibitory effect of
p66shc could be reduced by co-incubating with p189 (Fig. 2C,
lane 6 versus lane 5). To further address this question, a p66shc
P3A mutant was expressed (Fig. 2D, lane 4). Compared with
WT p66shc, the p66shc P3A mutant had impaired its binding to
Src (Fig. 2D, compare lane 1with lane 2). In addition, the bind-
ing ofWTp66shc to Src could not be disrupted by preincubation
with peptide 226, which contains the phosphorylated YXXV
(pYXXV) motif of Src, the binding site for p52shc (Fig. 2D, lane
2 versus lane 3). Further supporting data were obtained by
expressing the full-lengthWTCH2domain (Fig. 2E, lane 1) and
FIGURE 1. Inhibitory effect of p66shc on IGF-I signaling via disrupting SHPS-1p52shcGrb2 complex formation does not require its Grb2 binding ability.
All three cell types were serum-starved for 16 –18 h before adding IGF-I (100 ng/ml) for the indicated times. A, pSMC were transduced with pLenti-LacZ or
pLenti-HA p66shc Y349F/Y350F/Y427F (p66shc 3F) or pLenti-HA p66shc (p66shc WT) vector. Cell lysates were immunoblotted (IB) with an anti-HA antibody.
B, P66shc WT-, LacZ-, and p66shc 3F-overexpressing cell lysates were immunoprecipitated (IP) with an anti-Grb2 antibody and immunoblotted with an anti-Shc
antibody. To control for loading, the blot was reprobed for an anti-Grb2 antibody. p  0.05 (*) indicates a significant difference between LacZ cells and p66shc
WT or p66shc 3F cells at 10 min after IGF-I stimulation. C, the cell lysates were immunoprecipitated with an anti-SHPS-1 polyclonal antibody and immunoblotted
with anti-Tyr(P) (PY99), Shc, or Grb2 antibodies, respectively. To control for loading, the blot was immunoblotted with an anti-SHPS-1 antibody. p  0.05 (*) and
p  0.01 (**) indicate significant differences at 10 and 20 min after IGF-I stimulation between LacZ cells and p66shc WT or p66shc 3F cells. The figure is
representative of three independent experiments.
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P3A mutant CH2 domain (Fig. 2E, lane 2) and testing their
ability to bind to Src. The results showed that the WT CH2
domain, but not P3A mutant CH2 domain, could directly bind
to Src (Fig. 2E, lane 3 versus lane 4). Co-incubation of the CH2
domain peptide with p52shc and Src resulted in a 69  6%
decrease in p52shc-Src association (Fig. 2E, lane 6 versus lane 7),
but the P3Amutant CH2 domain had no effect (Fig. 2E, lane 8).
These in vitro binding assay results indicate that p66shc can
directly bind to Src through a PXXP-SH3 domain interaction,
and this impairs p52shc-Src association.
Because this interaction has the potential to lead to a confor-
mational change in Src that could impair either Src activation
or its ability to bind to p52shc, we investigated the effect of the
Src-p66shc interaction on these signaling events. In p66shc-over-
expressing cells, p66shc (HA) binding to Src occurred after 1
min of IGF-I treatment and did not further increase after 3 min
(Fig. 3A, 2.6-fold versus 3.0-fold). In LacZ cells, p66shc binding
to Src was increased after 1-min IGF-I treatment and further
enhanced after 3 min of IGF-I stimulation (Fig. 3A, 2.6-fold
versus 5.6-fold).However, the fold increase in LacZ- andp66shc-
overexpressing cells cannot be compared because, in order to
clearly show the increase in Src-associated p66shc in LacZ cells,
more cell lysate had to be used for co-immunoprecipitation.
The Src-p66shc interaction at 1 min could be significantly dis-
rupted by incubating with p189 (4.6-fold versus 2.8-fold),
whereas the 3-min interaction could only be partially disrupted
(Fig. 3B, 9.1-fold versus 5.2-fold). In contrast, p136, a peptide
containing the YXXVmotif of Src that binds to the SH2 domain
in p52shc, only reduces this interaction after 3-min of IGF-I
stimulation (Fig. 3B, 9.1-fold versus 4.8-fold) but not after 1min
of IGF-I stimulation. Incubating with both p189 and p136 had
an even greater effect after 3-min IGF-I stimulation (Fig. 3B,
9.1-fold versus 2.2-fold). To confirm that the response to p136
was due to the phosphorylated tyrosine, we examined these
interactions using a tyrosine-phosphorylated peptide, p226,
and nontransduced pSMC. Similar results were obtained (Fig.
3C). Of note, there was a slight variation in the effect of p136 or
p226 on p66shcSrc complex formation at 1 min of IGF-I treat-
ment (Fig. 3, B and C, lane 4 versus lane 2). However, after
standardization using total Src protein and pooling the results
from three independent experiments, no significant difference
was detected between IGF-I alone and IGF-I plus p136 or p226.
These data suggest that the binding of p66shc to Src is initially
mediated through PXXP-SH3domain interaction after 1min of
IGF-I stimulation and through both PXXP-SH3 and SH2-
Tyr(P) interactions after 3 min of IGF-I stimulation in living
cells.
To further address this question, we utilized mutagenesis of
full-length p66shc to disrupt the PXXP-SH3 domain interaction.
Three prolines in the CH2 domain of p66shc were substituted
with alanines. Expression of this mutant p66shc (p66shc P3A)
was verified by HA expression, and the expression level was
FIGURE 2. p66shc directly binds to Src through a polyproline-SH3 domain interaction in vitro. A, wild type p66shc (p66shc WT)-, LacZ-, and p66shc 3F-over-
expressing cells were serum-starved for 16 –18 h prior to the addition of IGF-I (100 ng/ml) for the indicated times. The cell lysates were immunoprecipitated (IP)
with an anti-Src antibody and immunoblotted (IB) with an anti-Shc antibody. To control for loading, the blots were stripped and reprobed with an anti-Src
antibody. B, analysis of potential interactions between Src and p66shc, including SH3 domain-polyproline interaction (SH3-PP) and the phosphotyrosine and
SH2 domain interaction (pY-SH2). C and D, the ability of p66shc, p52shc, or the p66shc P3A mutant to bind to Src and of the synthetic peptide p189 or p226 to
disrupt Src interaction with p66shc and p52shc was determined using in vitro binding assays as described under “Experimental Procedures.” E, the interaction of
intact CH2 domain or P3A-mutated CH2 domain and/or p52shc with Src was determined as described for C and D. 35S-Labeled p66shc, p52shc, p66shc (P3A), CH2,
and CH2 (P3A) were visualized by using a PhosphorImager. The figure is representative of at least two independent experiments.
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FIGURE 3. p66shc binds to Src through both polyproline-SH3 and SH2-phosphotyrosine interactions in living cells. A, pSMC were transduced with
pLenti-LacZ (LacZ) or pLenti-HA p66shc (p66shc WT) vector. Both cell types were serum-starved for 16 –18 h before stimulation with IGF-I (100 ng/ml) for the
indicated times. Cell lysates (p66shc WT, 500 g of protein; LacZ, 750 g of protein) were immunoprecipitated (IP) with an anti-Src antibody and immunoblotted
(IB) with an anti-Shc antibody. To control for loading, the blots were reprobed with anti-Src antibody. The arrow denotes the p66shc band. B and C, quiescent
LacZ cells (B) or non-transduced wild type pSMC (C) were preincubated with p189 and/or p136 or p226 (5 M) as indicated for 2 h and treated with IGF-I (100
ng/ml) for the indicated times. The cell lysates were immunoprecipitated with an anti-Src antibody and immunoblotted with an anti-Shc antibody. To control
the loading, the blot was reprobed with an anti-Src antibody. The arrow denotes the p66shc band. The ratio represents the densitometry value of Src-associated
p66shc divided by the densitometry value of total Src in each individual lane. D and E, cell lysates from quiescent wild type p66shc (p66shc WT)- and P47A/P48A/
P50A mutated p66shc (p66shc P3A)-overexpressing cells were analyzed for HA protein expression by immunoblotting with an anti-HA antibody. Quiescent
p66shc P3A-overexpressing cells were incubated with or without p189 or p136 (5 M) as indicated for 2 h before being exposed to IGF-I (100 ng/ml) for the
indicated times. The cell lysates were immunoprecipitated with an anti-Src antibody and immunoblotted with an anti-Shc antibody. The arrows denote the
p66shc and p52shc bands. p  0.05 (*) indicates that p136 preincubation significantly impairs p66shc and p52shc binding to Src after IGF-I stimulation, compared
with without a peptide or p189 preincubation in p66shc P3A cells (for D). p  0.01 (**) and p  0.001 (***) indicate that 3 min of IGF-I stimulation significantly
enhances p66shc and p52shc association with Src in p66shc P3A (for E). F, pSMC were transduced with pLenti-wild type Src (Src WT) or pLenti-Y329F/Y360F Src (Src
FF) vectors. Quiescent cells were incubated with or without p189 for 2 h and then stimulated with IGF-I (100 ng/ml) for the indicated times. Cell lysates were
immunoprecipitated with an anti-Src antibody, followed by immunoblotting with an anti-Shc antibody. To control for loading, the blot was reprobed with an
anti-Src antibody. The arrows denote the p66shc and p52shc bands. The figure is representative of three independent experiments.
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comparable with WT p66shc (p66shc WT) (Fig. 3D). Overex-
pression of p66shc P3A did not impair IGF-I-stimulated p66shc
binding to Src, which was clearly increased after 10 min (e.g.
4.03  0.52-fold increase above basal level after 10-min IGF-I
stimulation; p  0.05). In contrast to cells overexpressing WT
p66shc, Src-p52shc association was increased to a greater extent
(e.g. a 2.82  0.10-fold increase in p66shc P3A cells versus a
1.53  0.09-fold increase in p66shcWT cells after 10-min IGF-I
stimulation; p  0.01) (Fig. 3D versus Fig. 2A). This association
was not significantly affected by preincubating with p189,
which disrupts the PXXP-SH3 domain interaction. However,
preincubating with peptide p136, which blocks the SH2-Tyr(P)
interaction, inhibited both p66shc-Src (e.g. a 4.03  0.52-fold
increase with no peptide preincubation versus a 1.82  0.08-
fold increase with p136 preincubation after 10-min IGF-I stim-
ulation; p  0.05) and p52shc-Src interactions (e.g. a 2.82 
0.10-fold increase with no peptide preincubation versus a
1.72 0.10-fold increase with p136 preincubation after 10-min
IGF-I stimulation; p  0.05) (Fig. 3D). This suggested that
p66shc bound to Src via a SH2-Tyr(P) domain interaction in
p66shc P3A-overexpressing cells. Because analysis of the time
course of binding to each of the two sites indicated that the
PXXP/SH3 interaction occurred at 1 min after IGF-I stimula-
tion, a detailed time course analysis of this interaction using
cells expressing the mutant was undertaken. The results indi-
cated that a significant increase in IGF-I-dependent p66shc
binding to Src did not occur until 3 min of IGF-I treatment in
cells expressing p66shc P3A (e.g. a 4.73  0.12-fold increase
above basal level after 3-min IGF-I treatment; p  0.001) (Fig.
3E). Similarly, amajor increase in p52shc binding to Src could be
detected after 3min of exposure to IGF-I (e.g. a 3.56 0.16-fold
increase above basal level after 3-min IGF-I stimulation; p 
0.01) (Fig. 3E).We conclude that this interaction ismediated via
the SH2-Tyr(P) domain interaction, which can be disrupted by
p136 incubation (e.g. a 3.56  0.16-fold increase with no pep-
tide preincubation versus a 1.66  0.07-fold increase in p136
preincubation after 3-min IGF-I treatment; p  0.01) but not
p189 (e.g. a 3.56  0.16-fold increase with no peptide preincu-
bation versus a 4.16  0.17-fold increase with p189 preincuba-
tion after 3-min IGF-I treatment; p, not significant (NS)) (Fig.
3E). To further determine the importance of the YXX(V/L)-
SH2 domain interaction for p66shc binding, the two tyrosines in
Src that mediate the p52shc-Src interaction were substituted
with phenylalanines (Src FFmutant). Overexpression of the Src
FF mutant in pSMC significantly impaired both IGF-I-stimu-
lated p52shc and p66shc recruitment to Src, comparedwith over-
expression of Src WT after 5-min treatment (Fig. 3F). This
confirms that, like p52shc, p66shc also binds to Src through
SH2-Tyr(P) interaction after IGF-I stimulation. However, upon
IGF-I stimulation, an increase of p66shc bound to Src was still
detected in Src FF cells at the 1-min time point. That this is
mediated via the PXXP-SH3 interaction was confirmed by
showing that its binding could be disrupted by p189 preincuba-
tion. In contrast, there was no change of p52shc-Src interaction
after IGF-I stimulation in Src FF cells at the same time (Fig. 3F).
The Inhibitory Effect of p66shc on IGF-I-stimulated Down-
stream Signaling and Biological Actions Requires Its Binding to
Src via PXXP-SH3 Domain Interaction—Overexpression of
p66shc impaired IGF-I-stimulated p52shc phosphorylation com-
pared with cells expressing LacZ (e.g. a 1.84  0.07-fold
increase in LacZ cells versus a 1.15  0.10-fold increase in
p66shc WT cells after 10-min IGF-I stimulation; p  0.01) (Fig.
4A). This inhibition could be reduced by preincubation with
p189 (e.g. a 1.69  0.04-fold increase following p189 preincu-
bation versus a 1.15  0.10-fold increase with no peptide pre-
incubation after 10-min IGF-I stimulation; p 0.01) but not by
a control peptide (Fig. 4A). Similarly, overexpression of the
p66shc P3A mutant, which was comparable with WT p66shc
overexpression, had no inhibitory effect on IGF-I-stimulated
p52shc phosphorylation (e.g. a 2.39  0.09-fold increase in LacZ
cells versus a 2.19  0.05-fold increase in p66shc P3A cells after
10-min IGF-I stimulation; p, NS) (Fig. 4B). When downstream
signaling changes were analyzed usingWTp66shc-overexpress-
ing cells, incubation with p189 significantly increased IGF-I-
stimulatedMAPKactivation, comparedwith no peptide or pre-
incubation with a control peptide (e.g. a 7.88  0.23 fold versus
a 2.85  0.20-fold or 3.20  0.21-fold increase after 10-min
IGF-I stimulation; p  0.01) (Fig. 4C). Consistently, overex-
pression of p66shc P3A, unlike theWTp66shc, had no inhibitory
effect on IGF-I-stimulated Erk1/2 phosphorylation (e.g. a
4.25  0.24-fold increase in p66shc P3A cells versus a 4.85 
0.32-fold increase in LacZ cells after 10 min of IGF-I stimula-
tion; p  0.01) (Fig. 4D).
Because disruption of p66shc binding to Src through PXXP-
SH3 domain interaction significantly attenuated the inhibitory
effect of p66shc on IGF-I signal transduction, we determined
whether this change could lead to alterations of IGF-I-stimu-
lated biological actions. Overexpression of WT p66shc signifi-
cantly impaired IGF-I-stimulated cell proliferation, compared
with LacZ cells (1.35  0.05-fold versus 2.02  0.08-fold
increase (p  0.01), a 66% reduction compared with the maxi-
mal response) (Fig. 5A). However, overexpression of p66shcP3A
had no inhibitory effect on the IGF-I-stimulated cell prolifera-
tion, compared with LacZ cells (1.90  0.04-fold versus 2.02 
0.08-fold increase; p, NS) (Fig. 5A). Of note, for primary pSMC,
the maximum response to 10% fetal calf serum is only a 3-fold
increase in cell number in 48 h. Similarly, overexpression of
p66shc significantly attenuated the ability of IGF-I to stimulate
cell migration (1.53  0.09-fold versus 2.07  0.08-fold
increase, compared with LacZ cells (p  0.01), a 50% reduction
compared with the maximal response) (Fig. 5B). In contrast,
overexpression of p66shc P3A did not inhibit the ability of IGF-I
to stimulate cell migration, compared with LacZ cells (1.90 
0.03-fold versus 2.07  0.08-fold increase after IGF-I stimula-
tion; p, NS) (Fig. 5B).
Determination of theMechanismbyWhich p66shc Inhibits Src
Activation—We have previously shown that Src activation
(phosphorylation of Tyr419, equivalent to Tyr416 in chicken
Src), followed by phosphorylation of Tyr329 and Tyr360, is
required for Src-p52shc association (24). Because p66shc can
bind directly to Src after IGF-I stimulation independently of
Tyr329 and Tyr360 phosphorylation and this inhibits p52shc
phosphorylation, we determined if the binding of p66shc to Src
could alter IGF-I-stimulated Src activation. Cells expressing
p66shc short hairpin RNA showed a 87  2% decrease in p66shc
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FIGURE 4. Inhibitory effect of p66shc on IGF-I-stimulated p52shc tyrosine phosphorylation and MAPK activation is dependent on its binding to Src
through the polyproline-SH3 domain interaction. Quiescent LacZ-, wild type p66shc (p66shc WT)-, and p66shc P3A mutant-overexpressing cells were incu-
bated with or without the synthetic peptide 189 or control peptide for 2 h before adding IGF-I (100 ng/ml) for the indicated times. A and B, cell lysates were
immunoprecipitated (IP) with an anti-Tyr(P) (PY99) antibody and immunoblotted (IB) with an anti-Shc antibody. To control for loading, an equal amount of cell
lysate was immunoblotted with an anti-Shc antibody. p  0.01 (**) indicates a significant difference between two different treatments or the same treatment
in two cell types. The arrows denote the p52shc and p66shc bands. C and D, the same cell lysates were used to determine the Erk1/2 phosphorylation by probing
with an anti-phospho-Erk1/2 antibody. The blots were reprobed with an anti-Erk1/2 antibody to control for loading differences. p  0.01 (**) indicates a
significant difference between two different treatments or the same treatment in two cell types. The figure is representative of three independent experiments.
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(Fig. 6A) comparedwith empty vector control. IGF-I stimulated
Src tyrosine 419 phosphorylation (an index of Src activation)
after a 1-min treatment, and this response was enhanced by
p66shc knockdown (e.g. a 1.81  0.07-fold increase in EVC ver-
sus a 2.53  0.08-fold increase in p66shc Si; p  0.001) (Fig. 6A).
This suggests that constitutive expression of p66shc inhibits IGF-I-
dependent Src activation. To determine if p66shc inhibits Src
activation directly, we performed an in vitro Src kinase assay.
The results showed that p66shc directly inhibited Src activation
in a dose-dependent manner (Fig. 6, B and C, lane 2 versus lane
1; p  0.001). Because we had shown (Fig. 2) that p66shc inter-
actedwith Src through its PXXP sequence, we determined if the
short peptide containing this sequence p189 could inhibit Src
activation. The peptide alone had no effect (Fig. 6C, lane 7 ver-
sus lane 1; p, NS). However, p189 completely blocked the inhib-
itory effect of p66shconSrc activation (Fig. 6C, lane 5 versus lane
1; p, NS). Although p226, the peptide that blocked the SH2-
Tyr(P) interaction, was unable to completely abolish the inhib-
itory effect of WT p66shc on Src activity (Fig. 6C, lane 6 versus
lane 1; p  0.001), it partially rescued Src kinase activity in the
presence of WT p66shc (Fig. 6C, lane 6 versus lane 2; p  0.01).
However, it was much less effective than p189 (Fig. 6C, lane 6
versus lane 5; p  0.001). Interestingly, the CH2 domain alone
also impaired Src kinase activity (Fig. 6C, lane 4 versus lane 1;
p  0.01), but its effect was less than that of full-length WT
p66shc (Fig. 6C, lane 4 versus lane 2; p 0.001). Consistent with
the in vitro binding assay data, the P3A p66shcmutant and P3A
mutant CH2 domain, which do not bind to Src through the
PXXP-SH3 interaction, had no effect on Src kinase activity (Fig.
6, lanes 9 and 10 versus lane 1; p, NS). Similarly, p52shc also had
no effect on Src kinase activity (Fig. 6C, lane 11 versus lane 1; p,
NS). These data confirm that PXXP-SH3 interaction plays a
vital role in inhibition of Src activation. However, because full-
length p66shc had greater effect than the CH2 domain, this sug-
gests that the SH2-Tyr(P) interaction was also necessary for
maximal inhibition.
To determine the importance of the SH2-Tyr(P) interaction,
the SH2 domain of p66shcwas deleted, and themutant formwas
tested for its ability to inhibit Src kinase activity in vitro. This
p66shcmutantwas less effective than full-length p66shc (data not
shown). However, when the CH2 domain peptide and p52shc,
which binds to Src through SH2-Tyr(P) interaction,were added
together, therewas no additional effect comparedwith theCH2
domain alone (Fig. 6D, lane 3 versus lane 5; p, NS).
We used cell-permeable peptides to confirm these results
using living cells. IGF-I-stimulated Src activation was impaired
following overexpression of WT p66shc (e.g. a 2.46  0.15-fold
increase in LacZ versus a 1.49 0.10-fold increase in p66shcWT
after IGF-I stimulation; p  0.01), and this could be reduced by
preincubation with p189 (e.g. a 1.49  0.10-fold increase in
p66shcWT versus a 2.57 0.15-fold increase in p66shcWTwith
p189 preincubation after IGF-I stimulation; p 0.01) (Fig. 7A).
In addition, we showed that p189 could enhance IGF-I-stimu-
lated Src activation in wild type SMC (data not shown).
Although p136 was less effective than p189 in rescuing IGF-I-
stimulated Src activation (e.g. a 2.70  0.30-fold increase with
p136 preincubation versus a 3.53  0.46-fold increase in p189
preincubation after IGF-I stimulation; p  0.05, n  4), it had a
significant effect (e.g. a 2.70  0.30-fold increase in p136 prein-
cubation versus a 1.74  0.15-fold increase without preincuba-
tion after IGF-I stimulation in p66shcWT cells; p 0.05, n 4)
(Fig. 7B), suggesting that Tyr(P)-SH2 interaction between Src
and p66shc also plays a role in mediating the inhibitory effect of
p66shc on Src activation in living cells.
To confirm the results obtained using the peptides, the cells
expressing the p66shc P3A and p66shc SH2 mutants were uti-
lized. In cells expressing P3Amutant, IGF-I stimulated Src acti-
vation to the same extent as cells expressing LacZ (e.g. a 2.00 
0.10-fold increase in p66shc P3A cells versus a 2.05  0.10-fold
increase in LacZ cells after IGF-I stimulation; p, NS), whereas
cells expressingWT p66shc showed the inhibition of Src activa-
tion (e.g. a 2.05 0.10-fold increase in LacZ cells versus a 1.23
0.09-fold increase in p66shc WT cells after IGF-I stimulation;
p  0.01) (Fig. 7C). Consistent with peptide data, overexpres-
FIGURE 5. Inhibitory effect of p66shc on IGF-I-stimulated proliferation and
migration is dependent on its binding to Src through polyproline-SH3
interaction. Cell proliferation and migration were determined as described
under “Experimental Procedures.” A, comparison of the cell-proliferative
response to IGF-I (50 ng/ml) among wild type p66shc (p66shc WT)-, p66shc P3A-,
and LacZ-overexpressing cells, respectively. Each bar indicates the fold
increase over basal level and represents the pool of at least three indepen-
dent experiments. Cells overexpressing wild type p66shc showed a significant
impairment of IGF-I-stimulated cell proliferation, compared with control
LacZ- and p66shc P3A-overexpressing cells, respectively. B, comparison of cell
migration response to IGF-I (100 ng/ml) among p66shc WT-, p66shc P3A-, and
LacZ-overexpressing cells, respectively. Each bar indicates the fold increase
over basal and represents the pool of at least three independent experiments.
Overexpression of wild type p66shc significantly attenuated IGF-I-stimulated
cell migration, compared with LacZ- and p66shc P3A-overexpressing cells,
respectively.
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sion of p66shc SH2 (Fig. 7D), which eliminates the Tyr(P)-SH2
interaction between Src and p66shc, still inhibited IGF-I-stimu-
lated Src activation (e.g. a 2.68 0.24-fold increase in LacZ cells
versus a 1.86 0.10-fold increase in p66shc SH2; p 0.01), but
it was less effective than full-length p66shc (e.g. a 1.86  0.10-
fold increase in p66shc SH2 versus a 1.32  0.13-fold increase
in p66shc WT cells after IGF-I stimulation; p  0.05) (Fig. 7E).
Based on these data, we conclude that the full inhibitory effect
of p66shc on IGF-I-stimulated Src activation requires both
PXXP-SH3 and Tyr(P)-SH2 interactions but that the inhibitory
effect is initiated by the PXXP-SH3 interaction.
Examination of the Proposed Mechanism in Porcine Aortic
Endothelial Cells—Inorder to determinewhether the proposed
mechanism is unique for pSMCor is applicable for all other cell
types, we used the porcine aortic endothelial cells to examine
several pivotal results. We chose endothelial cells because they
express V3, Src, p66shc, and SHPS-1, the major components
affecting SHPS-1 complex formation and IGF-I signal trans-
duction, and they have been shown to respond to hyperglyce-
mia by increasing their sensitivity to IGF-I stimulation (28, 29).
Similar to pSMC, IGF-I stimulated p66shc association with Src
after 1- and 3-min treatment. The interaction at 1 min was
disrupted by p189, the polyproline and SH3 domain interaction
blocker, but not by tyrosine-phosphorylated p226. Both pep-
tides were able to cause some disruption of the interaction at 3
min after IGF-I stimulation (Fig. 8A), which is consistent with
the hypothesis that binding occurs through both sites. In addi-
tion, IGF-I stimulated Src activation after a 1-min treatment
(2.14  0.08-fold increase above the basal level; p  0.01), and
this stimulation was enhanced by p189 preincubation (addi-
tional 1.53 0.12-fold increase comparedwith IGF-I alone;p
0.01) but not a control peptide (Fig. 8B). To determine the effect
on downstream signaling, we examined the p52shc tyrosine phos-
phorylation and MAPK activation in response to IGF-I. IGF-I
stimulated p52shc tyrosine phosphorylation (2.77  0.22-fold
increase abovebasal;p0.01) andMAPKactivation (3.180.18-
fold increase above basal; p  0.01). Importantly, these responses
were enhanced by p189 but not a control peptide (Fig. 8,C andD).
Todetermine the effect of disruptionof Src-p66shc, on IGF-I-stim-
ulated biological actions, we examined IGF-I-stimulated cell pro-
liferation in the presence of p189 or a control peptide. IGF-I-stim-
ulated cell proliferation was enhanced by p189 preincubation
(1.870.09-fold versus2.380.08-fold increase after IGF-I treat-
ment; p 0.05), but exposure to the control peptide had no effect
(1.870.09-fold versus1.760.07-fold increase after IGF-I treat-
ment; p, NS) (Fig. 8E).
DISCUSSION
Our prior studies have shown that in response to hypergly-
cemia, a signaling complex composed of the scaffolding protein
FIGURE 6. p66shc impairs Src kinase activation through polyproline-SH3 domain interaction in vitro. A, after IGF-I treatment (100 ng/ml) for the indicated
times, the lysates from empty vector (EVC)- and p66shc short hairpin RNA template vector (p66shc Si)-transduced cells were used to determine the activation of
Src kinase by immunoblotting (IB) with an anti-phospho-Tyr419 Src antibody. The blot was reprobed with an anti-Src antibody to control for loading differences.
p  0.001 (***) indicates that knockdown of p66shc significantly enhances IGF-I-stimulated Src kinase activation, compared with EVC. B–D, p66shc, p52shc, p66shc
(P3A), CH2, and CH2 (P3A) were expressed using a cell-free system and then incubated with activated Src kinase, and the ability of Src to phosphorylate a
peptide substrate in vitro was determined as described under “Experimental Procedures.” The effect of p189 or p226 was also determined. p  0.05 (*), p  0.01
(**), and p  0.001 (***) indicate the significant differences between the treatment and control or between two different treatments. The figure is represent-
ative of three independent experiments.
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SHPS-1, SHP-2, Src, and p52shc is formed following IGF-I stim-
ulation. This complex is essential for IGF-I-stimulated p52shc
and MAPK activation and cell proliferation in vascular cell
types (7). p52shc is recruited to this complex by Src, which then
phosphorylates three tyrosines (24), leading to Grb2 recruit-
ment and MAPK activation. In contrast to p52shc, the p66shc
FIGURE 7. p66shc impairs IGF-I-stimulated Src kinase activation through polyproline-SH3 domain and SH2-phosphotyrosine interactions in living cells.
A–C, quiescent LacZ, WT p66shc (p66shc WT)-, and p66shc P3A-overexpressing cells were preincubated with or without p189 or p136 for 2 h before stimulation with IGF-I
(100 ng/ml) for the indicated times. The activation of Src kinase was measured by probing with an anti-phospho-Tyr419 Src antibody. The blots were reprobed with an
anti-Src antibody to control for loading differences. p  0.05 (*) and p  0.01 (**) indicate the significant differences between two different treatments or the same
treatment in two cell types. D, pSMC were transduced with pLenti-p66shc WT-HA (p66shc WT) or pLenti-p66shc SH2-HA (p66shc SH2) vector. Both cell types were
serum-starved for 16–18 h and analyzed for HA and p66shc protein expression. Cell lysates were immunoblotted with anti-HA and p66shc antibodies. The arrows denote
the 66-kDa and SH2-deleted p66shc forms. E, quiescent LacZ, p66shc WT, and p66shc SH2 cells were stimulated with IGF-I (100 ng/ml) for the indicated times. Cell lysates
were immunoblotted with an anti-phospho-Tyr419 Src antibody. To control for loading, the blot was reprobed with an anti-Src antibody. p  0.01 (**) and p  0.05 (*)
indicate the significant differences between two cell types. The figure is representative of at least three independent experiments. IB, immunoblot; Ctrl, control.
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isoform, which is also increased in response to hyperglycemia,
inhibits IGF-I-stimulated SHPS-1 complex formation and
p52shc recruitment to this complex, resulting in impaired Grb2
binding andMAPK activation, cell proliferation, andmigration
in response to IGF-I (10). In the present study, we have deter-
mined the mechanism by which p66shc disrupts IGF-I-stimu-
lated p52shc recruitment and activation. The results demon-
strate that p66shc sequentially binds to Src via a PXXP-SH3
interaction, followed by a SH2-Tyr(P) interaction, in response
to IGF-I, and this leads to impairment of IGF-I-stimulated Src
FIGURE 8. The proposed mechanism is also utilized in porcine aortic endothelial cells. A, endothelial cells were serum-starved for 16 –18 h and preincu-
bated with p189 or p226 (5 M) for 2 h before adding IGF-I (100 ng/ml) for the indicated times. The cell lysates were immunoprecipitated (IP) with an anti-Src
antibody and immunoblotted (IB) with an anti-Shc antibody. To control the loading, the blot was reprobed with an anti-Src antibody. The arrow denotes the
p66shc band. B, quiescent endothelial cells were preincubated with p189 or a control peptide (5 M) for 2 h before adding IGF-I (100 ng/ml) for 1 min. The
activation of Src kinase was measured by probing with an anti-phospho-Tyr419 Src antibody. The blots were reprobed with an anti-Src antibody to control for
loading differences. C, quiescent endothelial cells were preincubated with p189 or a control peptide (5 M) for 2 h before adding IGF-I (100 ng/ml) for 5 min. The
cell lysates were immunoprecipitated with an anti-Tyr(P) (pY99) antibody and immunoblotted with an anti-Shc antibody. To control the loading, an equal
amount of cell lysate was immunoblotted with an anti-Shc antibody. The arrow denotes the p52shc band. D, the same cell lysates were used to determine the
Erk1/2 phosphorylation by probing with an anti-phospho-Erk1/2 antibody. The blots were reprobed with an anti-Erk1/2 antibody to control for loading
differences. E, cell proliferation was determined as described under “Experimental Procedures”. Each bar indicates the fold increase over basal and represents
the pool of at least three independent experiments. p  0.01 (**) and p  0.001 (***) indicate the significant differences between two different treatments. The
figure is representative of three independent experiments.
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kinase activation, resulting in attenuated IGF-I-stimulated
p52shc phosphorylation and impaired MAPK activation, SMC
proliferation, and migration.
To understand how p66shc inhibits IGF-I-stimulated p52shc-
dependent signaling, several potential mechanisms were ana-
lyzed. Previous studies had proposed that EGF-dependent asso-
ciation ofGrb2with p66shc interferedwith the ability of Grb2 to
recruit SOS (son of sevenless), leading to attenuated activation
of MAPK (2), or that overexpression of p66shc competed with
p52shc for binding to a limited pool of Grb2, resulting in
impaired p52shc association and MAPK activation (9). In con-
trast, our results showed that p66shc 3Fmutant, which does not
bind toGrb2, still inhibited the recruitment of Grb2 to p52shc to
the same extent as wild type p66shc (Fig. 1C). Therefore, we
focused on the role of the unique CH2 domain of p66shc in
attenuating p52shc phosphorylation. Because a polyproline
sequence was identified in the p66shc CH2 domain and a SH3
domain is contained in Src, we investigated whether this inter-
action was modulating Src kinase activation. Our in vitro bind-
ing assay results showed that p66shc bound directly to the SH3
domain of Src through a PILPPLP sequence contained in the
CH2 domain. Further analyses using intact SMC indicated that
p66shc bound to Src not only via the PXXP-SH3 interaction but
also through a SH2 domain and Tyr(P) interaction in response
to IGF-I. Using specific blocking peptides and SMC expressing
a variety of mutants, we were able to show that these binding
interactions occurred sequentially after IGF-I stimulation, the
PXXP-SH3 interaction (detected at the 1 min time point)
occurring earlier than the SH2-Tyr(P) interaction (detected at
the 3 min time point). Importantly, similar results were
obtained in non-p66shc-overexpressing cells (LacZ cells) and
non-transduced wild type pSMC (Fig. 3, B and C).
Because extensive studies have shown that Src activation
depends on its conformational structure (30, 31), we investi-
gated if p66shc binding to Src would alter IGF-I-stimulated Src
kinase activation. The Src kinase domain is maintained in an
inactive state by intramolecular interactions (32, 33). Several
mechanisms have been proposed for activation of Src kinase,
including replacement of either SH2- or SH3-mediated in-
tramolecular interactions by high affinity ligands, such as auto-
phosphorylated platelet-derived growth factor receptor (34), a
PXXPmotif-containing protein (35); inactivation ofCsk (C-ter-
minal Src tyrosine kinase) and Chk (Csk homologous kinase);
and dephosphorylation of tyrosine 530 (equivalent to Tyr527 in
chick Src) by tyrosine phosphatases (36, 37). Herein, we report
a novel mechanism for regulating IGF-I-dependent Src kinase
activation. Our findings show that the CH2 domain of p66shc
contains a PXXPmotif that binds directly to the SH3 domain in
Src, and this complex formation initiates a series of events lead-
ing to the inhibition of Src activation. To our best knowledge,
this study is the first to show that a Src-SH3 domain-PXXP
ligand interaction can inhibit Src kinase activation in response
to stimuli. In contrast, the PXXP-SH3 interaction has been
shown to induce Src family kinase activation (35, 38, 39).
Although “turn on by a touch” is a widely accepted mechanism
for activation of Src and other members of the Src family
kinases, the actual steps leading to kinase activation are more
complex, and kinase activation depends on the spatial positions
and conformations of the SH3 and SH2 domains, the kinase
loop, the activation loop, and the C helix (40). Theoretically, an
alteration in any of these steps could prevent the kinase activa-
tion. Therefore, it is possible that the SH3 domain binding
interaction induces an allosteric change and thereby inhibits
Src kinase activation. In support of our observations, prior
studies have shown that proteins binding to Src family kinases
through non-SH3 domain interactions can inhibit kinase acti-
vation. These include the non-catalytic domain of Chk (41),
RACK1 (receptor of activated protein C kinase) (42), caveolin
(43), and Wiskott-Aldrich syndrome protein (44).
To understand the underlying mechanism of the inhibitory
effect of p66shc, several different approaches were employed. In
vitro kinase assays showed that full-length WT p66shc directly
inhibited Src kinase activity, and this inhibitory effect could be
reversed by the PXXP-SH3 blocking peptide. In addition, the
CH2 domain of p66shc had an inhibitory effect on Src kinase
activity, whereas p66shc P3A mutant and P3A-mutated CH2
domain had no effect on Src activation (Fig. 6). The studies
using living cells showed that IGF-I-stimulated Src activation
was significantly attenuated by overexpression of WT p66shc,
and this effect could be nullified by the addition of a peptide
containing the PXXP motif or enhanced by knockdown of
p66shc. Additionally, the expression of p66shc P3A mutant had
no effect on IGF-I-stimulated Src kinase activation in living
cells. These results clearly indicate that PXXP sequences in the
CH2 domain of p66shc interact with the SH3 domain in Src,
resulting in inhibition of Src kinase activation. Although the
PXXP regionmediates the inhibition, it is insufficient to inhibit
Src kinase activation, which requires the full-length CH2
domain. Of note, full-length p66shc had an even greater effect
than the CH2 domain, suggesting that the SH2 domain inter-
action with Tyr(P)329 or Tyr(P)360 in Src is required for maxi-
mal inhibition of Src activation. This prediction is supported
by the observation that the Tyr(P)-SH2 blocking peptide partially
attenuated the inhibitory effect of p66shc on Src kinase activity
in the in vitro kinase assay (Fig. 6C) and that it could partially
rescue IGF-I-stimulated Src activation in WT p66shc-overex-
pressing cells, although it was less effective than the PXXP-SH3
blocking peptide (Fig. 7B). However, once PXXP-SH3 interac-
tion was disrupted, the Tyr(P)-SH2 interaction no longer had
an effect on IGF-I-stimulated Src activation. This is consistent
with our results showing that expression of the full-length
p66shc P3A mutant was unable to inhibit IGF-I-stimulated Src
kinase activation. Therefore, we believe that SH3-PXXP inter-
action serves to initiate the inhibitory effect of p66shc on Src
activation in response to IGF-I and that the Tyr(P)-SH2 inter-
action also contributes to the inhibitory effect. Formation of
PXXP-SH3 interaction alone allowed some (but not complete)
inhibition by p66shc, even though the SH2-Tyr(P) interaction
could not be established (e.g. p66shc SH2 domain deletion) (Fig.
7, D and E). Our data indicate that simply occupying either of
the binding sites or both sites did not confer the full inhibitory
effect, since neither peptide itself could inhibit Src kinase activ-
ity (Fig. 6C), and the addition of the CH2 domain peptide plus
p52shc did not have an additional inhibitory effect compared
with CH2 peptide alone (Fig. 6D). Based on these results, we
postulate that IGF-I treatment triggers the conformation
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change of inactive (folded) Src and slightly opens its folded
structure. This allows the p66shc to bind to it via a PXXP-SH3
interaction. Meanwhile, after IGF-I treatment, Src autophos-
phorylates Tyr329 and Tyr360, which allows the further binding
to p66shc via a SH2-Tyr(P) interaction.When binding is present
at both sites, p66shc can significantly inhibit Src activation
either by preventing further Src unfolding or by inducing an
allosteric change to inactivate kinase activity. Our in vitro Src
kinase assay data clearly showed that at least the latter mecha-
nism was present because when p66shcwas added into the acti-
vated Src, the kinase activity of Src was significantly reduced
(Fig. 6C). To support this proposed model, RACK1 has been
reported to inhibit Src kinase activation via interaction through
multiple binding sites, including SH2 domain of Src, and acts as
a molecular chaperone to hold Src in the closed and inactive
conformational state (42). Similarly, Hsp90, a chaperone pro-
tein, has also been shown to hold v-Src in the inactive state,
thereby inhibiting its activation (45). In addition, this model
allows us to explain an interesting observation that shows that,
in LacZ cells, IGF-I stimulated p66shcSrc complex formation
after 1min of treatment, and the complex formation continued
increasing after 3 min of IGF-I treatment, whereas, in p66shc-
overexpressing cells, the maximal complex formation was
detected after 1min of IGF-I treatment, and no further increase
was detected at the 3 min time point (Fig. 3A). We believe that
is because, in p66shc-overexpressing cells, the formation a large
amount of the p66shcSrc complex via the PXXP-SH3 interac-
tion at 1 min inhibits Src autophosphorylation. Because Src
activation has been shown to be essential for phosphorylation
of Src Tyr329 and Tyr360 (24), which provide the binding sites
for SH2 domain in p66shc, this inhibition of Src kinase activity
limits the further increase of the complex formation via the
SH2-Tyr(P) interaction. By contrast, in LacZ cells, the degree of
increase in p66shc binding to Src via a PXXP-SH3 interaction at
1min does not significantly inhibit Src activation in response to
IGF-I, and this permits the formation of additional p66shcSrc
complex via the SH2-Tyr(P) interaction at the 3min time point.
Because the SH2-Tyr(P) interaction has a higher affinity than
PXXP-SH3 domain interaction, it is reasonable to expect the
greater p66shcSrc complex formation via the SH2-Tyr(P)
interaction at this time point. Consequently, it is not surpris-
ing that p136 or p226, both of which inhibit the SH2-Tyr(P)
interaction, has a greater inhibitory effect than p189 on the
formation of p66shcSrc complex after 3 min of IGF-I treat-
ment (Fig. 3, B and C).
Previous studies have shown that IGF-I activates Src kinase,
and this activation is critical for mediating IGF-I downstream
signaling, such as MAPK activation (24, 46, 47), Akt activation
(48), and IGF-I-stimulated biological actions (24, 49). To
understand the mechanism of Src-mediated IGF-I signaling,
previous studies focused on the identification of Src kinase sub-
strate, revealing that p52shc was a good candidate. Both in vitro
and in vivo data showed that activated Src can phosphorylate
p52shc on Tyr239/Tyr240/Tyr317 (50, 51). Our previous study
clearly demonstrated that, upon IGF-I stimulation, Src re-
cruited p52shc to the SHPS-1 signaling complex and phosphor-
ylated Tyr239/Tyr240/Tyr317 on p52shc, providing a binding site
for Grb2, thus activating downstream signaling in SMC (24).
This SHPS-1 complex formation is essential for IGF-I-stimu-
latedMAPK activation and biological actions (7). Disruption of
this complex formation by truncation of the SHPS-1 cytoplas-
mic domain (7) or Src silencing (24) or by overexpression of
p66shc (10) leads to impaired IGF-I signaling and biological
actions. Our previous and current data have shown that IGF-I-
induced Src activation is quite rapid and transient; the highest
level is detected at 1 min and then reduced after 3 or 5 min in
pSMC (24) (Figs. 6–8). Consistent with our findings, a similar
pattern in IGF-I-stimulated Src activation was observed in
preadipocytes (46). Consequently, an obvious question is how
this rapid and transient activated Src phosphorylates p52shc on
the SHPS-1 signaling complex and mediates MAPK activation
at the late time points. To address this question, we investigated
the kinetic activation of Src in response to IGF-I stimulation,
showing that the activation of Src occurred at 1min butwas still
greater than the basal activation level at 10 and 30 min after
IGF-I stimulation (supplemental Fig. 1A). More importantly,
we used co-immunoprecipitation to show that SHPS-1-associ-
ated p419Src (which phosphorylates p52shc) increased progres-
sively after 5 and 10minof IGF-I stimulation (supplemental Fig.
1B). These findings support our previous data indicating that
Src is recruited to the SHPS-1 complex and remains active at a
time when p52shc is phosphorylated, leading to Erk1/2 activa-
tion in response to IGF-I treatment. Because activation of IGF-I
signaling has been shown to inhibit hyperglycemia-induced
DNA damage (52) and activation of the mitochondrial apopto-
sis program (53), it is possible that a major increase in p66shc
may impair the ability of IGF-I to rescue cells under these con-
ditions. This is consistent with the observation that p66shc can
induce apoptosis under conditions of increased oxidative stress
or hyperglycemia (54).However, our findings suggest that these
responses are dependent upon the level of p66shc and Src
activation.
To expand the applicability of our findings, we examined the
proposedmechanism in the endothelial cells and confirmed the
pivotal molecular events that we observed in pSMC. Endothe-
lial cells express v3, Src, p66shc, and SHPS-1, which are
required for studying SHPS-1 signaling complex formation and
modulation of IGF-I signal transduction in hyperglycemia. In
addition, they have been shown to respond to hyperglycemia by
increasing their sensitivity to IGF-I stimulation (28, 29). There-
fore, we believe that this mechanism at least is applicable to
specific cell types that have the capability to respond to hyper-
glycemic and/or oxidative stress with an increase in prolifera-
tion in response to IGF-I.
In summary, our data demonstrate that p66shc sequentially
binds to Src through a PXXP-SH3 and a SH2-Tyr(P) interaction
in response to IGF-I. The PXXP-SH3 interaction plays a major
role in initiating the inhibition of IGF-I-stimulated Src kinase
activation; however, the full inhibitory effect requires the pres-
ence of the SH2-Tyr(P) interaction. This inhibition leads to
impairment of IGF-I-dependent p52shc tyrosine phosphoryla-
tion, MAPK activation, and IGF-I-stimulated cell proliferation
andmigration. Our findings provide novel information regard-
ing the regulation of Src kinase activation and suggest new pos-
sible strategies for inhibiting constitutively activated Src kinase
and p52shc signaling.
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